Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

Promising Trials in Immunotherapy

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
Promising Trials in Immunotherapy
Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028
Evan W Alley
University of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2015 on April 19, 2015 12:45 PM-2:55 PM
Promising Trials in Immunotherapy
Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001)
Edward B. Garon
David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
from AACR Annual Meeting 2015 on April 19, 2015 12:45 PM-2:55 PM
Promising Trials in Immunotherapy
Discussant
D. Ross Camidge
University of Colorado Denver, Aurora, CO, United States
from AACR Annual Meeting 2015 on April 19, 2015 12:45 PM-2:55 PM
Promising Trials in Immunotherapy
Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers
Janos L Tanyi
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2015 on April 19, 2015 12:45 PM-2:55 PM
Promising Trials in Immunotherapy
Discussant
Michel Sadelain
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2015 on April 19, 2015 12:45 PM-2:55 PM
Promising Trials in Immunotherapy
A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma
Mark R Middleton
University of Oxford, Oxford, United Kingdom
from AACR Annual Meeting 2015 on April 19, 2015 12:45 PM-2:55 PM
Promising Trials in Immunotherapy
Epstein-Barr virus-specific cytotoxic T lymphocytes for treatment of rituximab-refractory Epstein-Barr virus-associated lymphoproliferative disorder
Susan E Prockop
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2015 on April 19, 2015 12:45 PM-2:55 PM
Promising Trials in Immunotherapy
Discussant
Antoni Ribas
UCLA Medical Center, Los Angeles, CA, United States
from AACR Annual Meeting 2015 on April 19, 2015 12:45 PM-2:55 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8